Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

RNA interference

- PMLiVE

Pfizer’s Vyndaqel is first EU therapy for ATTR cardiomyopathy

EU approval will help drug achieve blockbuster status

- PMLiVE

Alnylam gains key NICE approval for Onpattro

Important milestone for company's first product

- PMLiVE

Akcea steals march on Alnylam with NICE approval

Advantage to Tegsedi over Onpattro

- PMLiVE

NICE says no to rival Alnylam and Akcea amyliodsis drugs – but deal could be done

Room for manoeuvre after initial rejection

- PMLiVE

Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe

Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines

- PMLiVE

Alnylam gets EU nod for Onpattro amid pricing backlash

However the drug’s price could be lowered in the EU due to direct competition

- PMLiVE

ICER says Alnylam’s Onpattro should cost 90%-95% less

Even after discounts the medication exceeds the cost-effectiveness threshold

- PMLiVE

Alnylam claims RNAi milestone with Onpattro approval

After years of ups and downs, triumph for gene-silencing tech

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links